Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-PD-32766 |
| Synonyms | |
| Therapy Description |
225Ac-PD-32766 is a radioconjugate comprising the radionuclide actinium-225 linked to a macrocyclic peptide targeting CA9, which potentially inhibits tumor growth (J of Nucl Med 2025 66: suppl_1 251069). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-PD-32766 | 225Ac-PD32766|225Ac-PD 32766|225[Ac]-PD32766|225[Ac]-PD-32766 | 225Ac-PD-32766 is a radioconjugate comprising the radionuclide actinium-225 linked to a macrocyclic peptide targeting CA9, which potentially inhibits tumor growth (J of Nucl Med 2025 66: suppl_1 251069). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07688187 | Phase I | 225Ac-PD-32766 | A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |